Harnessing Artificial Intelligence for the In Silico Design of Synergistic Antimicrobial Therapies Against Multidrug-Resistant Biofilms
Harnessing Artificial Intelligence for the In Silico Design of Synergistic Antimicrobial Therapies Against Multidrug-Resistant Biofilms
Arshia Attarian1 SarveAhrabi2
1) Department of Microbiology, TeMS.C., Islamic Azad University, Tehran, Iran. E-mail:
2) Department of Biology, CT.C., Islamic Azad University, Tehran, Iran. E-mail:
IOI Code
:
ABGZ-ABHKHE
Publication :
The third international conference on new approaches in engineering and basic sciences(icnabs.ir)
Abstract :
The escalation of antimicrobial resistance (AMR) and the recalcitrance of microbial biofilms have necessitated the exploration of novel therapeutic strategies. Traditional drug discovery is often hindered by high costs and slow clinical transition. Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative tools in streamlining the identification of potent antimicrobial agents. This review aims to synthesize recent advancements in utilizing AI-driven platforms for predicting synergistic interactions between plant-derived metabolites and conventional antibiotics, specifically targeting biofilm-forming pathogens. A comprehensive analysis of literature from 2018 to 2026 was conducted, focusing on deep learning models, molecular docking simulations, and QSAR modeling in the context of biofilm inhibition. Our findings indicate that AI-mediated virtual screening significantly enhances the hit rate for identifying multi-target inhibitors. Furthermore, in silico models effectively predict the disruption of Quorum Sensing (QS) pathways, offering a roadmap for precision treatment of chronic infections. Integrating AI into the drug discovery pipeline not only accelerates the identification of novel scaffolds but also provides a mechanistic understanding of synergistic antibiofilm activity, paving the way for personalized antimicrobial stewardship.
Keywords : artificial intelligence biofilm inhibition synergistic therapy in silico drug design multidrug resistance (mdr) machine learning